Business Context and Reporting Period
This Form 8-K is a current report filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc., as noted in the metadata request) on September 12, 2022. The filing discloses the appointment of a new Chief Financial Officer and related compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation details:
- Base Salary: $460,000 annually.
- Target Bonus: 40% of the annual base salary.
- Equity Grant: Option to purchase 225,000 shares of common stock.
- Vesting Schedule: 25% on the first anniversary, with the remainder vesting in equal monthly installments over the subsequent three years.
Material Changes
The primary material change reported is the appointment of Ryan Maynard as Chief Financial Officer, effective September 12, 2022. Mr. Maynard will serve as the Company's principal financial officer and principal accounting officer. He brings over 20 years of experience in biopharmaceutical finance, having previously served as CFO at LetsGetChecked, Blade Therapeutics, and Rigel Pharmaceuticals.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of risks and contingencies. It references standard severance and indemnification agreements for executive officers, which are incorporated by reference from prior filings.
Key Facts for Investor Verification
- Verify the exact vesting terms and exercise price of the 225,000 stock options granted to the new CFO.
- Review the full text of the Employment Agreement (Exhibit 10.1) for details on severance and indemnification.
- Confirm the impact of this leadership change on the company's financial reporting and strategic direction.
- Note that the filing explicitly states the press release and related exhibits are not deemed "filed" for purposes of Section 18 of the Exchange Act.